SAN DIEGO, March 17, 2021 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) today announced that "Get
Phexxi," its national direct-to-consumer (DTC) campaign aimed at
broadening awareness of its non-hormonal, on-demand birth control
method, Phexxi® (lactic acid, citric acid and
potassium bitartrate) vaginal gel, achieved significant initial
results.
"We believe the initial results from our "Get Phexxi" marketing
campaign demonstrate that we are achieving our goals for this
campaign: to raise awareness of this important birth control option
and to drive women to healthcare practices for Phexxi," said Evofem
Biosciences' CEO, Saundra Pelletier.
"We expect this ongoing campaign will continue to be an important
driver to advance the Phexxi uptake curve."
The "Get Phexxi" DTC commercial garnered over 173 million views
in just the first three weeks following the campaign launch on
Valentine's Day. This large reach has increased brand awareness and
impact as measured by key metrics including:
- A 73% increase in monthly ex-factory sales of Phexxi (unit
shipments from warehouse to wholesalers, each containing 12
single-dose Phexxi applicators) in February
2021, which included two weeks' data post-DTC launch, versus
the prior month.
- Ex-factory sales for the first quarter of 2021 exceeded levels
for full-year 2020 by March 12, 2021,
with over 9,100 units shipped quarter-to-date.
- More than 2,400 Phexxi units were dispensed in February 2021, a 30% increase over the prior
month, and total monthly prescriptions grew 32% to 2,349. Because
Phexxi is an on-demand contraceptive, and usage varies with the
frequency of a woman's sexual activity, some prescriptions of
Phexxi are for more than one unit.
- The number of healthcare providers prescribing Phexxi grew 25%
in February 2021 versus the prior
month. More than 3,050 healthcare providers have prescribed Phexxi
since its launch in September
2020.
The 2X increase in Phexxi total brand awareness at the end of
February (8%) over January (4%) also led to a 35X increase in
unpaid searches for "Phexxi" and a 180% increase in direct web
traffic going to Phexxi.com.
The "Get Phexxi" campaign highlights some of the struggles women
face when choosing among the many available methods of
contraception, whether it's the lack of control with condoms,
constant daily use of the pill, or abstinence required for
cycle tracking. The women featured in the commercial represent
the real-life drawbacks that Phexxi may help eliminate as a
hormone-free, on-demand birth control method.
To view the "Get Phexxi" commercial on demand, visit
https://www.youtube.com/watch?v=-i5Qyx6-SQA.
About Evofem Biosciences
Evofem Biosciences,
Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical
company committed to developing and commercializing innovative
products to address unmet needs
in women's sexual and reproductive health, including hormone-free, woman-controlled contraception
and protection from certain sexually transmitted infections (STIs).
The Company launched its first FDA-approved commercial
product, Phexxi® contraceptive vaginal gel, in the United States in September 2020. The Company's lead product
candidate, EVO100, is being evaluated for the prevention of
urogenital Chlamydia trachomatis and Neisseria
gonorrhoeae infection in women in the ongoing Phase 3 clinical
trial, 'EVOGUARD.' For more
information, please visit www.evofem.com.
Phexxi® is a registered trademark of
Evofem Biosciences, Inc.
About PHEXXI®
Phexxi® is an
on-demand method of birth control used to prevent pregnancy.
Phexxi® is
not effective when used after sex.
IMPORTANT SAFETY INFORMATION
- If you have had a history of repeated urinary tract infections
or other urinary tract problems, avoid Phexxi®.
- The most common side effects were vaginal burning, vaginal
itching, vaginal yeast infection, urinary tract infection, vaginal
area discomfort, bacterial vaginosis, vaginal discharge, genital
discomfort (including male partners), and pain while
urinating.
- Phexxi® does not protect against any sexually
transmitted infections, including HIV.
- Contact your healthcare provider if you are experiencing severe
genital irritation or discomfort or urinary tract symptoms.
For more information about Phexxi®, talk to your
healthcare provider and see full Product Information, which is
available at
https://www.phexxi.com/themes/custom/phexxiDTC/dist/pdf/PhexxiUSPI.pdf.
Please report side effects by contacting Evofem Biosciences®
toll-free at 1-833-EVFMBIO
or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Forward-Looking Statements
This press release
includes "forward-looking statements," within the meaning of the
safe harbor for forward-looking statements provided by Section 21E
of the Securities Exchange Act of 1934, as amended, and the
Private Securities Litigation Reform Act of 1995 including, without
limitation, statements regarding the implications of key metrics
and the and the expected impact of the "Get Phexxi" campaign on
consumer behavior, brand uptake, and future growth of Phexxi and
the Company. Various factors could cause actual results to differ
materially from those discussed or implied in the forward-looking
statements, and you are cautioned not to place undue reliance on
these forward-looking statements, which are current only as of the
date of this press release. Each of these forward- looking
statements involves risks and uncertainties. Important factors that
could cause actual results to differ materially from those
discussed or implied in the forward looking statements, or that
could impair the value of Evofem Biosciences' assets and business,
are disclosed in the Company's SEC filings, including its Annual
Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on
March 4, 2021. All forward-looking
statements are expressly qualified in their entirety by such
factors. The Company does not undertake any duty to update any
forward-looking statement except as required by law. This press
release contains estimates and other statistical data made by
independent parties and by the Company relating to market size and
growth and other data about its industry. Phexxi brand awareness is
measured by monthly surveys conducted by an independent third-party
research group among women at risk for pregnancy. These estimates,
statistical data, and estimates of brand awareness involve a number
of assumptions and limitations, and you are cautioned not to give
undue weight to such estimates.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc. araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact
Ellen
Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490 -3248
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-dtc-campaign-get-phexxi-delivers-strong-initial-impact-301249007.html
SOURCE Evofem Biosciences, Inc.